Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Esperion Therapeutis.Inc. sell Northland Securities

Start price
16.03.23 / 50%
Target price
Performance (%)
This prediction is currently active. The price of Esperion Therapeutis.Inc. has decreased since the start of the prediction. Compared to the start price this results in a performance of -25.50%. This prediction currently runs until 16.03.24. The prediction end date can be changed by Northland_Securities at any time. Northland_Securities has 50% into this prediction

Esperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.

Performance without dividends (%)
Name 1w
Esperion Therapeutis.Inc. -20.252%
iShares Core DAX® 0.284%
iShares Nasdaq 100 -0.713%
iShares Nikkei 225® 0.598%
iShares S&P 500 -2.171%

Comments by Northland_Securities for this prediction

In the thread Esperion Therapeutis.Inc. diskutieren

Esperion Therapeutics, Inc. (NASDAQ: ESPR) was downgraded by analysts at Northland Securities from a "market perform" rating to an "underperform" rating.
Ratings data for ESPR provided by MarketBeat